Chroma Medicine Overview
- Year Founded
-
2020
- Status
-
Acquired/Merged
- Employees
-
113
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$75M
- Investors
-
1
Chroma Medicine General Information
Description
Developer of genomic medicines designed to revolutionize the treatment of genetically driven diseases. The company's medicines harness epigenetics, nature's innate mechanism for gene regulation programmable epigenetic editors to target genes and control chromatin conformation by coupling a DNA binding domain with epigenetic effector domains, enabling medical practitioners to have a class of therapeutics to achieve unparalleled control of gene expression.
Contact Information
Website
www.chromamedicine.comCorporate Office
- 201 Brookline Avenue
- Suite 1101
- Boston, MA 02215
- United States
Corporate Office
- 201 Brookline Avenue
- Suite 1101
- Boston, MA 02215
- United States
Chroma Medicine Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 04-Dec-2024 | $75M | Completed | Out of Business | ||
| 3. Early Stage VC (Series B) | 08-Feb-2023 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 12-Oct-2021 | $101M | $127M | Completed | Generating Revenue | |
| 1. Seed Round | 01-Jan-2021 | $26.3M | $26.3M | Completed | Generating Revenue |
Chroma Medicine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Seed | 24,583,572 | $0.000100 | $0.06 | $1.07 | $1.07 | 1x | $1.07 | 14.05% |
Chroma Medicine Comparisons
Industry
Financing
Details
Chroma Medicine Competitors (3)
One of Chroma Medicine’s 3 competitors is Neuron23, a Venture Capital-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Neuron23 | Venture Capital-Backed | South San Francisco, CA | ||||
| Casma Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA |
Chroma Medicine Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Chroma Medicine Patents
Chroma Medicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240382621-A1 | Compositions and methods for epigenetic regulation of hbv gene expression | Pending | 15-May-2023 | ||
| US-20240382622-A1 | Compositions and methods for epigenetic regulation of hbv gene expression | Pending | 15-May-2023 | ||
| US-20240132855-A1 | Compositions and methods for epigenetic regulation of hbv gene expression | Inactive | 23-Sep-2022 | ||
| AU-2023289695-A1 | Compositions and methods for epigenetic regulation of b2m expression | Pending | 23-Jun-2022 | ||
| EP-4519293-A1 | Compositions and methods for epigenetic regulation of pcsk9 expression | Pending | 01-May-2022 | C07K14/4703 |
Chroma Medicine Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Chroma Medicine Former Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARCH Venture Partners | Venture Capital | Minority | ||
| Alexandria Real Estate Equities | Real Estate | Minority | ||
| Atlas Venture | Venture Capital | Minority | ||
| Casdin Capital | Venture Capital | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority |
Chroma Medicine Acquisitions (1)
Chroma Medicine’s most recent deal was a Merger/Acquisition with Epsilen Bio. The deal was made on 17-Nov-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Epsilen Bio | 17-Nov-2021 | Merger/Acquisition | Drug Discovery |
Chroma Medicine FAQs
-
When was Chroma Medicine founded?
Chroma Medicine was founded in 2020.
-
Where is Chroma Medicine headquartered?
Chroma Medicine is headquartered in Boston, MA.
-
What is the size of Chroma Medicine?
Chroma Medicine has 113 total employees.
-
What industry is Chroma Medicine in?
Chroma Medicine’s primary industry is Drug Discovery.
-
Is Chroma Medicine a private or public company?
Chroma Medicine is a Private company.
-
What is the current valuation of Chroma Medicine?
The current valuation of Chroma Medicine is .
-
What is Chroma Medicine’s current revenue?
The current revenue for Chroma Medicine is .
-
How much funding has Chroma Medicine raised over time?
Chroma Medicine has raised $262M.
-
Who are Chroma Medicine’s investors?
ARCH Venture Partners, Alexandria Real Estate Equities, Atlas Venture, Casdin Capital, and Cormorant Asset Management are 5 of 15 investors who have invested in Chroma Medicine.
-
Who are Chroma Medicine’s competitors?
Neuron23, Casma Therapeutics, and Intellia Therapeutics are competitors of Chroma Medicine.
-
When was Chroma Medicine acquired?
Chroma Medicine was acquired on 04-Dec-2024.
-
Who acquired Chroma Medicine?
Chroma Medicine was acquired by nChroma Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
